Prolonged Hematogone Expansion Is Associated with Better Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.

IF 1.2 Q4 HEMATOLOGY

Hematology Reports Pub Date : 2025-09-10 DOI:10.3390/hematolrep17050046

Bianca Serio, Danilo De Novellis, Marisa Gorrese, Angela Bertolini, Paola Manzo, Francesca Picone, Anna Maria Della Corte, Rossella Marcucci, Denise Morini, Michela Rizzo, Roberto Guariglia, Serena Luponio, Pasqualina Scala, Francesco Verdesca, Anna Maria Sessa, Francesca Velino, Martina De Leucio, Maddalena Langella, Valentina Giudice, Carmine Selleri

{"title":"Prolonged Hematogone Expansion Is Associated with Better Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.","authors":"Bianca Serio, Danilo De Novellis, Marisa Gorrese, Angela Bertolini, Paola Manzo, Francesca Picone, Anna Maria Della Corte, Rossella Marcucci, Denise Morini, Michela Rizzo, Roberto Guariglia, Serena Luponio, Pasqualina Scala, Francesco Verdesca, Anna Maria Sessa, Francesca Velino, Martina De Leucio, Maddalena Langella, Valentina Giudice, Carmine Selleri","doi":"10.3390/hematolrep17050046","DOIUrl":null,"url":null,"abstract":"Background/Objectives: Hematogones, B cell precursors, are considered a clock of bone marrow reconstitution after chemotherapy and hematopoietic stem cell transplantation (HSCT). Methods: In this retrospective observational monocentric study, we investigated the prognostic role of hematogone expansion after allogeneic HSCT and its association with clinical and molecular features. Results: Using a cut-off value of 0.1%, hematogones were detected in 60% of patients at the first re-evaluation after HSCT (median, 2.4%; range, 0.2-9.0%) and in 63% of subjects at the most recent evaluation (MRR) (median, 1.4%; range, 0.1-5.1%). In particular, prolonged hematogone expansion was associated with longer overall survival (p = 0.0043) and relapse-free survival (p = 0.0002). No associations were described between hematogone frequency and stem cell sources or acute or chronic graft versus host disease incidence. Conclusions: In conclusion, our results confirmed that hematogones mirrored bone marrow fitness and reconstitution ability; thus, they could be used as a prognostic marker of HSCT outcomes.","PeriodicalId":12829,"journal":{"name":"Hematology Reports","volume":"17 5","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12452376/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/hematolrep17050046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/Objectives: Hematogones, B cell precursors, are considered a clock of bone marrow reconstitution after chemotherapy and hematopoietic stem cell transplantation (HSCT). Methods: In this retrospective observational monocentric study, we investigated the prognostic role of hematogone expansion after allogeneic HSCT and its association with clinical and molecular features. Results: Using a cut-off value of 0.1%, hematogones were detected in 60% of patients at the first re-evaluation after HSCT (median, 2.4%; range, 0.2-9.0%) and in 63% of subjects at the most recent evaluation (MRR) (median, 1.4%; range, 0.1-5.1%). In particular, prolonged hematogone expansion was associated with longer overall survival (p = 0.0043) and relapse-free survival (p = 0.0002). No associations were described between hematogone frequency and stem cell sources or acute or chronic graft versus host disease incidence. Conclusions: In conclusion, our results confirmed that hematogones mirrored bone marrow fitness and reconstitution ability; thus, they could be used as a prognostic marker of HSCT outcomes.

查看原文本刊更多论文

同种异体造血干细胞移植受者长时间的造血扩增与更好的预后相关。

背景/目的：造血细胞是B细胞的前体，被认为是化疗和造血干细胞移植（HSCT）后骨髓重建的时钟。方法：在这项回顾性观察性单中心研究中，我们研究了同种异体造血干细胞移植后红细胞扩增的预后作用及其与临床和分子特征的关系。结果：使用0.1%的截断值，60%的患者在造血干细胞移植后第一次重新评估时检测到造血细胞（中位数，2.4%；范围，0.2-9.0%），63%的患者在最近一次评估（MRR）中检测到造血细胞（中位数，1.4%；范围，0.1-5.1%）。特别地，延长的造血扩张与更长的总生存期（p = 0.0043）和无复发生存期（p = 0.0002）相关。没有描述造血频率与干细胞来源或急性或慢性移植物抗宿主病发病率之间的关联。结论：总之，我们的研究结果证实了造血细胞反映了骨髓的适应性和重建能力；因此，它们可以作为HSCT结果的预后指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊